Tag:
Quark Pharmaceuticals
Latest Headlines
Latest Headlines
Quark Pharma plots $20M IPO
Fresh off its big deal with Novartis, Quark Pharmaceuticals has announced that it plans to pursue a $20 million IPO. The company had previously backed away from a $86.25 million IPO in March 2007.
Novartis options Quark program in $680M pact
Underscoring the rich potential of new siRNA therapeutics, Novartis has agreed to pay Quark Pharmaceuticals up to $680 million to nail the licensing rights to a new therapy for kidney-related
Quark, Nitto Denko collaborate on fibrotic diseases
Quark Pharmaceuticals, a Fremont, CA-based developer of RNAi-based therapeutics, is collaborating with Nitto Denko, a diversified materials manufacturer based in Osaka, Japan, to develop siRNA
Igenica leads a trio of new venture rounds
There's a trio of new biotech financing rounds to report today. Igenica, a cancer antibody start-up based in Burlingame, CA, is reporting that it raised $24 million in a Series B. The new round was
Quark prepares for human trials of siRNA therapy
Quark Pharmaceuticals says the FDA has approved its IND application for DGFi, an experimental siRNA drug for kidney transplant patients. "We are pleased with the FDA acceptance of our DGFi IND
Quark Pharma snares $27M for RNAi work
Quark Pharmaceuticals has garnered $27 million in a new round of venture financing. The RNAi developer attracted the support of SBI Asset Management and SBI Investment, subsidiaries of the
